欢迎访问《现代生物医学进展》编辑部！

目的：探讨IHCP+CDS 治疗晚期子宫内膜癌的临床疗效和安全性。方法：选取治疗确诊为晚期子宫内膜癌的患者84 例，随机分为观察组和对照组。观察组采用IHCP+CDS方案化疗，对照组采用常规灌注+肿瘤细胞减灭术方案化疗。比较两组的手术时间、临床疗效、复发率、生存时间和不良反应等。结果：观察组手术时间和术中腹水量比对照组少，两组差异明显(P<0.05)；观察组总有效率和24 个月生存率比对照组高，而复发率比对照组低(P<0.05)；观察组恶心、麻木发生率较对照组低(P<0.05)；而白细胞降低、血小板降低和盆腔感染方面相互比较，无显著差异(P>0.05)。结论：IHCP+CDS能有效改善晚期子宫内膜癌患者术前和术后对化疗的耐受性；提高患者的生存率和临床治疗效果。

英文摘要:

Objective:To explore the clinical effect and safety of cytoreductive surgery (CDS) combined with intraperitoneal hyperthermic chemoperfusion (IHCP) treatment on advanced endometrial carcinoma.Methods:The diagnosed 84 cases of advanced endometrial carcinoma patients were divided randomly into observing group and control group. Patients in observing group were treated with IHCP+CDS, and those in control group were treated with ordinary chemotherapy+ CDS. Compare the operation time, clinical curative effect, recurrence rate, survival time and adverse reaction between two groups.Results:The operation time was shorter and intraoperative ascites was less in observing group than in control group, and the difference was statistical (P<0.05). The total effective rate and 24-month survival rate was better in observing group than in control group (P<0.05). The observing group also had a lower reoccurrence rate than the control group (P<0.05). The incidences of nausea and numbness were lower in observing group than in control group (P <0. 05); but there was no significant difference between two groups in leukopenia, thrombocytopenia and pelvic infection.Conclusion:IHCP+CDS could improve the general situation of preoperative advanced endometrial cancer, preoperative and postoperative chemotherapy tolerance, and the survival and clinical patient outcomes.

View Full Text View/Add Comment Download reader